Christina Esdar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christina Esdar has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Nina Linde
The healthcare business of Merck KGaA, Darmstadt, Germany
81 shared publications - Christine Drechsler
The healthcare business of Merck KGaA, Darmstadt, Germany
79 shared publications - Agnieszka Wozniak
KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute Leuven, Belgium
54 shared publications - Jasper Verreet
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium
54 shared publications - Lore De Cock
KU Leuven 1 Laboratory of Experimental Oncology, Department of Oncology, Leuven Cancer Institute Leuven, Belgium
54 shared publications - Luna De Sutter
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium
54 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 3 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 3. One histologically representative picture of H&E staining per treatment group in the experiment with GIST882KIT13.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 3 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 3. One histologically representative picture of H&E staining per treatment group in the experiment with GIST882KIT13.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 6 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 6. One histologically representative picture of cPARP staining in control group versus IDRX-42_25 treatment group in the experiment with UZLX-GIST9KIT11+17.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 6 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 6. One histologically representative picture of cPARP staining in control group versus IDRX-42_25 treatment group in the experiment with UZLX-GIST9KIT11+17.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 2 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 2. Individual absolute tumor volumes per experiment and per treatment group on the first and last day of experiment.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 2 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 2. Individual absolute tumor volumes per experiment and per treatment group on the first and last day of experiment.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 1 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 1. Histopathological characteristics.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 1 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 1. Histopathological characteristics.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 5 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 5. Average number of apoptotic cells per treatment group in 10 high power fields assessed on (A) hematoxylin and eosin (H&E) staining and on (B) cleaved poly-ADP-ribose-polymerase (cPARP) staining.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 5 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 5. Average number of apoptotic cells per treatment group in 10 high power fields assessed on (A) hematoxylin and eosin (H&E) staining and on (B) cleaved poly-ADP-ribose-polymerase (cPARP) staining.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. 4 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 4.(A) Average number of mitotic cells per treatment group in 10 high power fields assessed on phospho-histone H3 (pHH3) immunostaining and (B) percentage of proliferative cells per treatment group per 5 high-power fields assessed on Ki-67 immunostaining.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. 4 from Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line–Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST)
Supplementary Fig. 4.(A) Average number of mitotic cells per treatment group in 10 high power fields assessed on phospho-histone H3 (pHH3) immunostaining and (B) percentage of proliferative cells per treatment group per 5 high-power fields assessed on Ki-67 immunostaining.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. A, Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT inhibitors. 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line. B, X-ray structures of M4205 (2.1 Å resolution; PDB ID: 7ZW8) in complex with the kinase domain of wild-type KIT. For clarity, only interacting residues are shown including H-bonds and Van der Waals contacts (depicted as dashed black and brown lines, respectively). C, Potent biochemical inhibition of clinically relevant KIT mutations in exon 11, exon 13/14, and exon 17 is demonstrated for M4205 compared with approved KIT inhibitors imatinib, sunitinib, and ripretinib. IC50 values show mean with SD of two technical replicates. D, Cellular target engagement of KIT-mutant forms with M4205 is confirmed in NanoBRET assays. Target coverage is determined by competitive displacement of the NanoBRET tracer with 1, 10, or 100 nmol/L M4205 and is shown as mean with SD of two technical replicates.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Discovery of M4205, a potent inhibitor of disease-relevant KIT-mutant variants. A, Schematic overview of clinically observed mutations in different domains of the RTK KIT and estimated target coverage (green: positive; red: negative) of approved and investigational KIT inhibitors. 1L, first-line; 2L, second-line; 3L, third-line; 4L, fourth-line. B, X-ray structures of M4205 (2.1 Å resolution; PDB ID: 7ZW8) in complex with the kinase domain of wild-type KIT. For clarity, only interacting residues are shown including H-bonds and Van der Waals contacts (depicted as dashed black and brown lines, respectively). C, Potent biochemical inhibition of clinically relevant KIT mutations in exon 11, exon 13/14, and exon 17 is demonstrated for M4205 compared with approved KIT inhibitors imatinib, sunitinib, and ripretinib. IC50 values show mean with SD of two technical replicates. D, Cellular target engagement of KIT-mutant forms with M4205 is confirmed in NanoBRET assays. Target coverage is determined by competitive displacement of the NanoBRET tracer with 1, 10, or 100 nmol/L M4205 and is shown as mean with SD of two technical replicates.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Dose- and exposure-dependent inhibition of KIT autophosphorylation with M4205 in the GIST430/654 model. A, Tumor-bearing mice were treated daily with three different doses of M4205 for 5 days, and inhibition of KIT autophosphorylation compared with untreated controls was determined at different time points after last treatment. B, Free plasma concentrations of M4205 were plotted against the effect of KIT inhibition which revealed an in vivo IC50 of 4 nmol/L. C–E, Inhibition of KIT autophosphorylation is correlated with free plasma concentration over time for the three dosage groups (dashed line: 4 nmol/L free in vivo IC50; dotted line: 16 nmol/L free cellular IC50).
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Dose- and exposure-dependent inhibition of KIT autophosphorylation with M4205 in the GIST430/654 model. A, Tumor-bearing mice were treated daily with three different doses of M4205 for 5 days, and inhibition of KIT autophosphorylation compared with untreated controls was determined at different time points after last treatment. B, Free plasma concentrations of M4205 were plotted against the effect of KIT inhibition which revealed an in vivo IC50 of 4 nmol/L. C–E, Inhibition of KIT autophosphorylation is correlated with free plasma concentration over time for the three dosage groups (dashed line: 4 nmol/L free in vivo IC50; dotted line: 16 nmol/L free cellular IC50).
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Mouse PK and human dose prediction
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer
Mouse PK and human dose prediction